Most ranking pages soft-pedal exclusions. This page is the blunt filter.
Who Should Not Take It?
| Situation | Why it matters | Better next step |
|---|---|---|
| Nitrate therapy (for example some angina medicines) | Classic absolute contraindication for sildenafil and tadalafil on FDA labels | Talk to the prescribing clinicians; do not self-stack |
| Told never to use PDE5 drugs | QUAD still contains two PDE5 actives in the 2026 brand list | Follow that prior medical advice |
| Needs FDA-approved finished combo for coverage or policy | Compounded QUAD is not an approved finished combination | Ask about labeled generics |
| Has not tried generic sildenafil or tadalafil | Cost and complexity are usually higher with a 4-in-1 kit | Consider a single-agent path first |
| Unwilling to manage auto-renew | Subscription cancel friction is a documented complaint theme | Read cancel terms or choose a non-subscription clinic |
Detail pages: MEDVi Quad and nitrates, side effects, legitimacy.
Up: review
Sources Checked for This Page
- FDA labels for sildenafil, tadalafil, and bremelanotide (Vyleesi) for ingredient-class facts, not as approval of the QUAD combo.
- FDA warning letter MEDVi 721455 (20 February 2026) where brand trust context is relevant.
- 2026 brand-facing MEDVi QUAD price, cancel, shipping, and formula statements treated as seller claims.
Individual ingredients such as sildenafil and tadalafil are FDA-approved for other indications; the combined compounded formulation has not been evaluated by the FDA as a finished product, standard for all compounded medicines.
This content is informational, not medical advice.